Hormonal
Endothelial function, measured by flow-mediated dilation, progressively declines across the stages of the menopause transition, independent of traditional cardiovascular risk factors and age.
For women in the perimenopausal and postmenopausal stages, maintaining cardiovascular health requires extra attention to vascular markers like blood pressure and cholesterol, as the protective effect of estrogen declines. This period is a critical window for lifestyle interventions to preserve endothelial function and reduce long-term cardiovascular risk.
Our findings suggest that a decline in endothelial function begins during the early stages of menopause (perimenopause) and worsens with the loss of ovarian function and prolonged estrogen deficiency.
Why this rating
Cross-sectional study with a relatively large sample size (n=132) and rigorous control for confounders, but lacks longitudinal causality.
Source
Endothelial Function Is Impaired across the Stages of the Menopause Transition in Healthy Women
Kerrie L. Moreau et al. · The Journal of Clinical Endocrinology & Metabolism · 2012
DOI 10.1210/jc.2012-2244
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →